Literature DB >> 22336956

Celecoxib pathways: pharmacokinetics and pharmacodynamics.

Li Gong1, Caroline F Thorn, Monica M Bertagnolli, Tilo Grosser, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22336956      PMCID： PMC3303994          DOI： 10.1097/FPC.0b013e32834f94cb

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  93 in total

1.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

2.  Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.

Authors:  S K Paulson; J D Hribar; N W Liu; E Hajdu; R H Bible; A Piergies; A Karim
Journal:  Drug Metab Dispos       Date:  2000-03       Impact factor: 3.922

Review 3.  Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.

Authors:  D Clemett; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 4.  Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.

Authors:  Debabrata Mukherjee
Journal:  Biochem Pharmacol       Date:  2002-03-01       Impact factor: 5.858

5.  Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial.

Authors:  Arnold B Alper; Holly Tomlin; Usha Sadhwani; Andrew Whelton; Jules Puschett
Journal:  Am J Ther       Date:  2006 May-Jun       Impact factor: 2.688

6.  Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line.

Authors:  Sebastien Arico; Sophie Pattingre; Chantal Bauvy; Pierre Gane; Alain Barbat; Patrice Codogno; Eric Ogier-Denis
Journal:  J Biol Chem       Date:  2002-05-08       Impact factor: 5.157

7.  Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner.

Authors:  Hadas Dvory-Sobol; Efrat Cohen-Noyman; Diana Kazanov; Arie Figer; Shlomo Birkenfeld; Liora Madar-Shapiro; Robert Benamouzig; Nadir Arber
Journal:  Eur J Cancer       Date:  2006-01-19       Impact factor: 9.162

8.  The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks.

Authors:  Amy J Johnson; Ao-Lin Hsu; Ho-Pi Lin; Xueqin Song; Ching-Shih Chen
Journal:  Biochem J       Date:  2002-09-15       Impact factor: 3.857

9.  Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.

Authors:  Julia Kirchheiner; Elke Störmer; Christian Meisel; Nadine Steinbach; Ivar Roots; Jürgen Brockmöller
Journal:  Pharmacogenetics       Date:  2003-08

10.  Celecoxib activates a novel mitochondrial apoptosis signaling pathway.

Authors:  Verena Jendrossek; René Handrick; Claus Belka
Journal:  FASEB J       Date:  2003-06-17       Impact factor: 5.191
View more
  38 in total

1.  A Comparison of the Anti-Inflammatory Effects of Cis-9, Trans-11 Conjugated Linoleic Acid to Celecoxib in the Collagen-Induced Arthritis Model.

Authors:  Jake M Olson; Alexander W Haas; Jennifer Lor; Holly S McKee; Mark E Cook
Journal:  Lipids       Date:  2017-01-11       Impact factor: 1.880

2.  Drug-gene interactions: inherent variability in drug maintenance dose requirements.

Authors:  Paul Westervelt; Kihoon Cho; David R Bright; David F Kisor
Journal:  P T       Date:  2014-09

Review 3.  The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation.

Authors:  Li Di; Amanda Balesano; Samantha Jordan; Sophia M Shi
Journal:  AAPS J       Date:  2021-01-07       Impact factor: 4.009

4.  Integration analysis of metabolites and single nucleotide polymorphisms improves the prediction of drug response of celecoxib.

Authors:  Xiaoqing Xing; Pengcheng Ma; Qing Huang; Xiemin Qi; Bingjie Zou; Jun Wei; Lei Tao; Lingjun Li; Guohua Zhou; Qinxin Song
Journal:  Metabolomics       Date:  2020-03-14       Impact factor: 4.290

Review 5.  Cytochrome P450 interactions and clinical implication in rheumatology.

Authors:  Audrey Cayot; Davy Laroche; Anne Disson-Dautriche; Anaïs Arbault; Jean-Francis Maillefert; Paul Ornetti
Journal:  Clin Rheumatol       Date:  2014-06-14       Impact factor: 2.980

6.  Synergistic antiproliferative effects of curcumin and celecoxib in hepatocellular carcinoma HepG2 cells.

Authors:  Fatma M Abdallah; Maged W Helmy; Mohamed A Katary; Asser I Ghoneim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-28       Impact factor: 3.000

Review 7.  New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.

Authors:  Honor J Hugo; C Saunders; R G Ramsay; E W Thompson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-07-21       Impact factor: 2.673

8.  Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis.

Authors:  Charles A Kunos; Kathryn Winter; Adam P Dicker; William Small; Fadi W Abdul-Karim; Dawn Dawson; Anuja Jhingran; Richard Valicenti; Joanne B Weidhaas; David K Gaffney
Journal:  Int J Gynecol Cancer       Date:  2013-05       Impact factor: 3.437

9.  Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine.

Authors:  Tokunbo Yerokun; Leyte L Winfield
Journal:  Anticancer Res       Date:  2015-12       Impact factor: 2.480

Review 10.  Effects of Nonsteroidal Anti-Inflammatory Drugs at the Molecular Level.

Authors:  Caner Gunaydin; S Sirri Bilge
Journal:  Eurasian J Med       Date:  2018-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.